Sign Out
Darunavir/Ritonavir Tablets 400 mg/50 mg is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection.
Darunavir/Ritonavir Tablets 400 mg/50 mg may be used to provide suitable dose regimens for the treatment of HIV-1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are: antiretroviral therapy (ART)-naïve (see Dosage & Administration); ART-experienced with no darunavir resistance associated mutations (DRV-RAMs) and who have plasma HIV-1 RNA <100,000 copies/ml and CD4+ cell count ≥100 cells x 106/l. In deciding to initiate treatment with Darunavir in such ART-experienced patients, genotypic testing should guide the use of Darunavir (see Dosage & Administration, Contraindications, Precautions and Pharmacology: Pharmacodynamics under Actions).
